Credit Suisse Ag Akebia Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.32 - $0.67 $104,072 - $217,902	-325,227 Reduced 100.0%	5 $0
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $1,053 - $4,286	1,463 Added 0.45%	325,232 $233,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $208,833 - $308,629	92,404 Added 39.94%	323,769 $732,000
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $307,318 - $507,403	130,774 Added 130.01%	231,365 $666,000
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $200,233 - $297,166	-70,754 Reduced 41.29%	100,591 $380,000
Q1 2021 May 14, 2021	SELL	$2.92 - $5.06 $1.34 Million - $2.31 Million	-457,201 Reduced 72.74%	171,345 $580,000
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $84,948 - $144,641	-38,265 Reduced 5.74%	628,546 $1.76 Million
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $1.09 Million - $5.96 Million	455,630 Added 215.75%	666,811 $1.67 Million
Q2 2020 Aug 12, 2020	BUY	$6.67 - $13.58 $870,848 - $1.77 Million	130,562 Added 161.95%	211,181 $2.87 Million
Q1 2020 May 13, 2020	SELL	$4.1 - $10.24 $97,579 - $243,712	-23,800 Reduced 22.79%	80,619 $611,000
Q4 2019 Feb 12, 2020	SELL	$3.16 - $6.73 $69,283 - $147,555	-21,925 Reduced 17.35%	104,419 $660,000
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $80,265 - $122,094	22,610 Added 21.8%	126,344 $495,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $9,286 - $18,233	2,265 Added 2.23%	103,734 $501,000
Q1 2019 May 14, 2019	BUY	$5.41 - $8.73 $33,450 - $53,977	6,183 Added 6.49%	101,469 $831,000
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $348,986 - $592,435	64,747 Added 212.01%	95,286 $527,000
Q3 2018 Nov 13, 2018	SELL	$7.44 - $10.65 $114,479 - $163,871	-15,387 Reduced 33.5%	30,539 $270,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $64,617 - $80,083	-7,062 Reduced 13.33%	45,926 $458,000
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $79,079 - $130,112	8,298 Added 18.57%	52,988 $506,000
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $120,342 - $165,555	8,451 Added 23.32%	44,690 $664,000
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $167,664 - $252,523	12,838 Added 54.86%	36,239 $712,000
Q2 2017 Aug 14, 2017	BUY	N/A	23,401	23,401 $336,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$20.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$18 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.3 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.51 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.65 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account